Thermo Fisher Scientific

TMO · NYSE · USD

$654.80+0.35%+$2.29

Close · October 2, 2026

At a glance

Revenue growth: +3.91%; 2025 vs 2024
Net income growth: +5.82%; 2025 vs 2024
Net margin: 15.0%; 2024: 14.8%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Balance sheet · Annual
Item	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Total assets	110,343	97,321	98,726	97,154	95,123	69,052	58,381	56,232	56,669	45,908
Current assets	28,707	22,137	24,589	25,229	20,113	21,957	11,893	10,625	9,421	7,021
Cash and equivalents	9,852	4,009	8,077	8,524	4,477	10,325	2,399	2,103	1,335	786
Short-term investments	253	1,561	3.0	—	—	—	—	—	—	—
Receivables	10,566	9,626	9,664	9,427	8,945	6,472	4,952	4,595	3,879	3,427
Inventory	5,425	4,978	5,088	5,634	5,051	4,029	3,370	3,005	2,971	2,213
Net property, plant and equipment	12,012	10,795	11,004	10,873	9,864	6,687	5,448	4,165	4,047	2,578
Goodwill	49,362	45,853	44,020	41,196	41,924	26,041	25,714	25,347	25,290	21,328
Other intangible assets	15,838	15,533	16,670	17,478	20,146	12,685	14,014	14,978	16,684	13,969
Long-term investments	438	438	534	154	63.0	53.0	67.0	64.0	32.0	37.0
Current liabilities	15,189	13,332	14,012	17,010	13,436	10,304	6,197	6,147	7,048	4,866
Accounts payable	3,622	3,079	2,872	3,381	2,867	2,175	1,920	1,615	1,428	926
Long-term debt	35,648	28,859	31,405	28,784	32,148	19,146	17,089	17,848	18,997	15,482
Total debt	40,855	30,561	36,711	35,848	33,817	22,591	17,827	18,426	20,172	15,784
Total liabilities	56,807	47,650	51,884	53,006	54,146	34,535	28,706	28,646	31,256	24,368
Total equity (incl. minority)	53,536	49,671	46,842	44,148	40,977	34,517	29,675	27,586	25,413	21,540
Retained earnings	59,156	53,102	47,364	41,910	35,431	28,116	22,092	18,696	15,914	13,927
Minority interest	129	87.0	107	170	184	10.0	—	—	—	—